Preclinical evidence showed that tumor and stroma cells release C–C motif chemokine ligand 2 (CCL2) to recruit monocytes expressing C-C chemokine receptor type 2 (CCR2); these recruited CCR2-expressing monocytes will finally polarize into TAMs, contributing to tumor cell survival [31,32,33]. This evidence concerns the gene CCR2 and neoplasm.